메뉴 건너뛰기




Volumn 52, Issue 6, 2010, Pages 832-838

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

Author keywords

HCV; HCV RNA assays; Response guided therapy; Sensitivity; Treatment duration

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

EID: 77952429312     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.030     Document Type: Article
Times cited : (52)

References (33)
  • 2
    • 0034461502 scopus 로고    scopus 로고
    • Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics
    • Lee S.C., Antony A., Lee N., Leibow J., Yang J.Q., Soviero S., et al. Improved version 2.0 qualitative and quantitative Amplicor reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 38 (2000) 4171-4179
    • (2000) J Clin Microbiol , vol.38 , pp. 4171-4179
    • Lee, S.C.1    Antony, A.2    Lee, N.3    Leibow, J.4    Yang, J.Q.5    Soviero, S.6
  • 3
    • 0034082547 scopus 로고    scopus 로고
    • Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination
    • Gerken G., Rothaar T., Rumi M.G., Soffredini R., Trippler M., Blunk M.J., et al. Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 38 (2000) 2210-2214
    • (2000) J Clin Microbiol , vol.38 , pp. 2210-2214
    • Gerken, G.1    Rothaar, T.2    Rumi, M.G.3    Soffredini, R.4    Trippler, M.5    Blunk, M.J.6
  • 4
    • 0036175978 scopus 로고    scopus 로고
    • Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay
    • Ross R.S., Viazov S., Sarr S., Hoffmann S., Kramer A., and Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods 101 (2002) 159-168
    • (2002) J Virol Methods , vol.101 , pp. 159-168
    • Ross, R.S.1    Viazov, S.2    Sarr, S.3    Hoffmann, S.4    Kramer, A.5    Roggendorf, M.6
  • 5
    • 0033802570 scopus 로고    scopus 로고
    • Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
    • Sarrazin C., Teuber G., Kokka R., Rabenau H., and Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 32 (2000) 818-823
    • (2000) Hepatology , vol.32 , pp. 818-823
    • Sarrazin, C.1    Teuber, G.2    Kokka, R.3    Rabenau, H.4    Zeuzem, S.5
  • 7
    • 34547395999 scopus 로고    scopus 로고
    • Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method
    • Chevaliez S., Bouvier-Alias M., Brillet R., and Pawlotsky J.M. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46 (2007) 22-31
    • (2007) Hepatology , vol.46 , pp. 22-31
    • Chevaliez, S.1    Bouvier-Alias, M.2    Brillet, R.3    Pawlotsky, J.M.4
  • 8
    • 66749184153 scopus 로고    scopus 로고
    • Performance of the Abbott m2000SP/m2000RT Real-time polymerase chain reaction assay for hepatitis C virus RNA quantification
    • Chevaliez S., Bouvier-Alias M., and Pawlotsky J.M. Performance of the Abbott m2000SP/m2000RT Real-time polymerase chain reaction assay for hepatitis C virus RNA quantification. J Clin Microbiol 47 (2009) 1726-1732
    • (2009) J Clin Microbiol , vol.47 , pp. 1726-1732
    • Chevaliez, S.1    Bouvier-Alias, M.2    Pawlotsky, J.M.3
  • 9
    • 33846063686 scopus 로고    scopus 로고
    • Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA
    • Michelin B.D., Muller Z., Stelzl E., Marth E., and Kessler H.H. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 38 (2007) 96-100
    • (2007) J Clin Virol , vol.38 , pp. 96-100
    • Michelin, B.D.1    Muller, Z.2    Stelzl, E.3    Marth, E.4    Kessler, H.H.5
  • 10
    • 50849137806 scopus 로고    scopus 로고
    • Evaluation of an automated, highly sensitive, real-time PCR-based assay (Cobas Ampliprep/Cobas TaqMan) for quantification of HCV RNA
    • Sarrazin C., Dragan A., Gartner B.C., Forman M.S., Traver S., Zeuzem S., et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (Cobas Ampliprep/Cobas TaqMan) for quantification of HCV RNA. J Clin Virol 43 (2008) 162-168
    • (2008) J Clin Virol , vol.43 , pp. 162-168
    • Sarrazin, C.1    Dragan, A.2    Gartner, B.C.3    Forman, M.S.4    Traver, S.5    Zeuzem, S.6
  • 11
    • 33644889424 scopus 로고    scopus 로고
    • Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5
    • Sarrazin C., Gärtner B., Sizmann D., Babiel R., Mihm U., Hofmann W.P., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44 (2006) 729-737
    • (2006) J Clin Microbiol , vol.44 , pp. 729-737
    • Sarrazin, C.1    Gärtner, B.2    Sizmann, D.3    Babiel, R.4    Mihm, U.5    Hofmann, W.P.6
  • 12
    • 57349116917 scopus 로고    scopus 로고
    • Differences between two real-time PCR based assays (RealTime HCV, Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for HCV RNA detection and quantification
    • Vermehren J., Kau A., Gartner B.C., Gobel R., Zeuzem S., and Sarrazin C. Differences between two real-time PCR based assays (RealTime HCV, Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for HCV RNA detection and quantification. J Clin Microbiol 46 (2008) 3880-3891
    • (2008) J Clin Microbiol , vol.46 , pp. 3880-3891
    • Vermehren, J.1    Kau, A.2    Gartner, B.C.3    Gobel, R.4    Zeuzem, S.5    Sarrazin, C.6
  • 13
    • 33947133809 scopus 로고    scopus 로고
    • Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the Cobas AmpliPrep/Cobas TaqMan system
    • Sizmann D., Boeck C., Boelter J., Fischer D., Miethke M., Nicolaus S., et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the Cobas AmpliPrep/Cobas TaqMan system. J Clin Virol 38 (2007) 326-333
    • (2007) J Clin Virol , vol.38 , pp. 326-333
    • Sizmann, D.1    Boeck, C.2    Boelter, J.3    Fischer, D.4    Miethke, M.5    Nicolaus, S.6
  • 14
    • 20544443172 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
    • Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
    • (2005) N Engl J Med , vol.352 , pp. 2609-2617
    • Mangia, A.1    Santoro, R.2    Minerva, N.3    Ricci, G.L.4    Carretta, V.5    Persico, M.6
  • 15
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    • Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
    • (2006) Hepatology , vol.43 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3    Pockros, P.J.4    Reddy, K.R.5    Hadziyannis, S.J.6
  • 16
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 (2006) 97-103
    • (2006) J Hepatol , vol.44 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3    Sperl, J.4    Horsmans, Y.5    Cianciara, J.6
  • 17
    • 34147207791 scopus 로고    scopus 로고
    • A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
    • Yu M.L., Dai C.Y., Huang J.F., Hou N.J., Lee L.P., Hsieh M.Y., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 (2007) 553-559
    • (2007) Gut , vol.56 , pp. 553-559
    • Yu, M.L.1    Dai, C.Y.2    Huang, J.F.3    Hou, N.J.4    Lee, L.P.5    Hsieh, M.Y.6
  • 18
    • 38649090068 scopus 로고    scopus 로고
    • Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
    • Dalgard O., Bjoro K., Ring-Larsen H., Bjornsson E., Holberg-Petersen M., Skovlund E., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 (2008) 35-42
    • (2008) Hepatology , vol.47 , pp. 35-42
    • Dalgard, O.1    Bjoro, K.2    Ring-Larsen, H.3    Bjornsson, E.4    Holberg-Petersen, M.5    Skovlund, E.6
  • 19
    • 48749099989 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    • Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135 (2008) 451-458
    • (2008) Gastroenterology , vol.135 , pp. 451-458
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3    Gschwantler, M.4    Maieron, A.5    Brunner, H.6
  • 20
    • 38649090347 scopus 로고    scopus 로고
    • Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial
    • Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carretta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47 (2008) 43-50
    • (2008) Hepatology , vol.47 , pp. 43-50
    • Mangia, A.1    Minerva, N.2    Bacca, D.3    Cozzolongo, R.4    Ricci, G.L.5    Carretta, V.6
  • 21
    • 46249114151 scopus 로고    scopus 로고
    • Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial
    • Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47 (2008) 1884-1893
    • (2008) Hepatology , vol.47 , pp. 1884-1893
    • Yu, M.L.1    Dai, C.Y.2    Huang, J.F.3    Chiu, C.F.4    Yang, Y.H.5    Hou, N.J.6
  • 22
    • 34447318385 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    • Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
    • (2007) N Engl J Med , vol.357 , pp. 124-134
    • Shiffman, M.L.1    Suter, F.2    Bacon, B.R.3    Nelson, D.4    Harley, H.5    Sola, R.6
  • 23
    • 68949183162 scopus 로고    scopus 로고
    • Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
    • Berg T., Weich V., Teuber G., Klinker H., Moller B., Rasenack J., et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 50 (2009) 369-377
    • (2009) Hepatology , vol.50 , pp. 369-377
    • Berg, T.1    Weich, V.2    Teuber, G.3    Klinker, H.4    Moller, B.5    Rasenack, J.6
  • 24
    • 77951432006 scopus 로고    scopus 로고
    • Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
    • Epub ahead of print
    • Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010 [Epub ahead of print].
    • Hepatology , pp. 2010
    • Diago, M.1    Shiffman, M.L.2    Bronowicki, J.P.3    Zeuzem, S.4    Rodriguez-Torres, M.5    Pappas, S.C.6
  • 25
    • 33645992473 scopus 로고    scopus 로고
    • Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    • Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
    • (2006) Gastroenterology , vol.130 , pp. 1086-1097
    • Berg, T.1    von Wagner, M.2    Nasser, S.3    Sarrazin, C.4    Heintges, T.5    Gerlach, T.6
  • 26
    • 33746564989 scopus 로고    scopus 로고
    • Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    • Sanchez-Tapias J.M., Diago M., Escartin P., Enriquez J., Romero-Gomez M., Barcena R., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006) 451-460
    • (2006) Gastroenterology , vol.131 , pp. 451-460
    • Sanchez-Tapias, J.M.1    Diago, M.2    Escartin, P.3    Enriquez, J.4    Romero-Gomez, M.5    Barcena, R.6
  • 27
    • 37749051824 scopus 로고    scopus 로고
    • Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    • Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
    • (2007) Hepatology , vol.46 , pp. 1688-1694
    • Pearlman, B.L.1    Ehleben, C.2    Saifee, S.3
  • 28
    • 60749103034 scopus 로고    scopus 로고
    • A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C
    • Ide T., Hino T., Ogata K., Miyajima I., Kuwahara R., Kuhara K., et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 104 (2009) 70-75
    • (2009) Am J Gastroenterol , vol.104 , pp. 70-75
    • Ide, T.1    Hino, T.2    Ogata, K.3    Miyajima, I.4    Kuwahara, R.5    Kuhara, K.6
  • 29
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose
    • Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6
  • 30
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    • Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
    • (2003) Hepatology , vol.38 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.G.3    Manns, M.P.4    Harvey, J.5    Albrecht, J.6
  • 31
    • 0037371144 scopus 로고    scopus 로고
    • Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    • Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
    • (2003) Hepatology , vol.37 , pp. 600-609
    • Berg, T.1    Sarrazin, C.2    Herrmann, E.3    Hinrichsen, H.4    Gerlach, T.5    Zachoval, R.6
  • 32
    • 41849102023 scopus 로고    scopus 로고
    • Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods
    • Carlsson T., Quist A., and Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol 80 (2008) 803-807
    • (2008) J Med Virol , vol.80 , pp. 803-807
    • Carlsson, T.1    Quist, A.2    Weiland, O.3
  • 33
    • 0035020530 scopus 로고    scopus 로고
    • Effects of storage and type of blood collection tubes on hepatitis C virus level in whole blood samples
    • Kessler H.H., Stelzl E., Raggam R.B., Haas J., Kirchmeir F., Hegenbarth K., et al. Effects of storage and type of blood collection tubes on hepatitis C virus level in whole blood samples. J Clin Microbiol 39 (2001) 1788-1790
    • (2001) J Clin Microbiol , vol.39 , pp. 1788-1790
    • Kessler, H.H.1    Stelzl, E.2    Raggam, R.B.3    Haas, J.4    Kirchmeir, F.5    Hegenbarth, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.